SUBSCRIBE
SUBSCRIBE
News   Drug Development

ImmuPharma plc CEO Slams Stock Plunge After Drug Trial

November 19, 2009 | 
1 min read
Bookmark and Share

Reuters -- The head of lupus specialist ImmuPharma said mid-stage trial results for its lead drug were encouraging and should not have prompted a 19 percent drop in the share price on Thursday.
Clinical research Phase 2
MORE ON THIS TOPIC
Concept of saving money with a pink colored piggy bank held in a hand in front of a blackboard with hand drawn coins
Weight loss
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
February 23, 2026
 · 
4 min read
 · 
Annalee Armstrong
Insights
Historic ALS Investment Signals New Treatment Momentum
February 23, 2026
 · 
3 min read
 · 
Jennifer Smith-Parker
Insights
Redefining Obesity Treatment Beyond GLP-1 Limits
February 19, 2026
 · 
1 min read
 · 
Jennifer Smith-Parker
Insights
Muscle Preservation, Tolerability and Alternative Administration Routes Define Obesity’s Drug Future
February 19, 2026
 · 
2 min read
 · 
Jennifer Smith-Parker